Clinical Trials Decriminalization Patients Safety 
NORML
JANUARY 4, 2019
Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. NH resident? GA resident?
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Published Via JD Supra. The state of the law on psychedelic substances is in flux.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
AUGUST 31, 2021
The researchers stated that these knowledge gaps must be addressed and that “clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”. The researchers did note however that only 2.9%
Cannabis Law Report
MAY 29, 2022
7] And cities around the country are beginning to decriminalize some psychedelics, with advocates for decriminalization citing the potential medical benefits. In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., Clinical Trials and Human Subject Protections.
Cannabis Law Report
MARCH 7, 2019
Switzerland’s government will allow 5,000 citizens to use cannabis legally, as part of a country-wide clinical trial. Lawmakers backed scientific studies into the impact of cannabis on public health and safety, ahead of potential regulation, however any rule change is unlikely to occur in the next decade unless fast-tracked.
The Cannigma
AUGUST 26, 2021
Medical: Legal Recreational: Illegal (though at least one territory has adopted decriminalization). The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions.
The Blunt Truth
AUGUST 13, 2019
On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is also meeting with other federal agencies and state counterparts, trade organizations, and patient groups in a quest for data.
Expert insights. Personalized for you.
126 
Let's personalize your content